Hong Thieu
Plus aucun poste en cours
Profil
Hong Thieu worked as an Investment Director at Estag Capital AG and as a Chief Financial Officer at KeyNeurotek Pharmaceuticals AG from 2006 to 2009.
He obtained an undergraduate degree from the University of Siegen.
Anciens postes connus de Hong Thieu
| Sociétés | Poste | Fin |
|---|---|---|
Estag Capital AG
 Estag Capital AG Investment ManagersFinance estag Capital AG is an independent Berlin-based venture capital firm which was founded in 1998 to invest in very early-stage companies. | Directeur en chef des Investissements | 01/01/2011 |
KeyNeurotek Pharmaceuticals AG
 KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Directeur Financier/CFO | - |
Formation de Hong Thieu
| University of Siegen | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
Estag Capital AG
Estag Capital AG Investment ManagersFinance estag Capital AG is an independent Berlin-based venture capital firm which was founded in 1998 to invest in very early-stage companies. | Finance |
